Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
about
Non-alcoholic fatty liver disease: what the clinician needs to know.Micronutrient Antioxidants and Nonalcoholic Fatty Liver DiseaseThe Natural Course of Non-Alcoholic Fatty Liver DiseaseRole of Serum Uric Acid and Ferritin in the Development and Progression of NAFLDRole of BAF60a/BAF60c in chromatin remodeling and hepatic lipid metabolismGut Microbiota and Lifestyle Interventions in NAFLDNAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms?Implication of hepatokines in metabolic disorders and cardiovascular diseasesType 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the SpotlightCurrent Management of NAFLDNAFLD and Chronic Kidney DiseaseRelationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?TM6SF2 E167K Variant, a Novel Genetic Susceptibility Variant, Contributing to Nonalcoholic Fatty Liver DiseaseResearch advances in the relationship between nonalcoholic fatty liver disease and atherosclerosisDietary approach in the treatment of nonalcoholic fatty liver diseaseNutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin ResistanceAssociation of Nonalcoholic Fatty Liver Disease with Subclinical Cardiovascular Changes: A Systematic Review and Meta-AnalysisEpigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutritionEpidemiology of fatty liver: an updateNon-alcoholic fatty liver disease: a practical approach to diagnosis and stagingNonalcoholic fatty liver disease: new treatmentsEfficacy of Berberine in Patients with Non-Alcoholic Fatty Liver DiseaseNoninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound TechniqueNonalcoholic fatty liver disease and vascular disease: state-of-the-art.Iron and non-alcoholic fatty liver diseaseDefinitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic ReviewNovel treatment options for lysosomal acid lipase deficiency: critical appraisal of sebelipase alfaNonalcoholic fatty liver disease - A multisystem disease?Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?Sirtuins and nonalcoholic fatty liver diseaseIncreased risk of nonalcoholic fatty liver disease with occupational stress in Chinese policemen: A 4-year cohort studyOmic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease.NAFLD and liver transplantation: Current burden and expected challenges.Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field.Serum aminotransferase ratio is independently correlated with hepatosteatosis in patients with HCV: a cross-sectional observational study.Non-invasive score identifies ultrasonography-diagnosed non-alcoholic fatty liver disease and predicts mortality in the USA.Portal Hypertension Complications Are Frequently the First Presentation of NAFLD in Patients Undergoing Liver Transplantation Evaluation.Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study.Caspase-2 promotes obesity, the metabolic syndrome and nonalcoholic fatty liver disease.Association of Non-alcoholic Fatty Liver Disease with Conduction Defects on Electrocardiogram.
P2860
Q24563068-CE8CF2A2-0392-486E-A8F0-47ACA1E21350Q26738646-DB6F4C7E-D1E4-44E6-A47F-B29C6F3F03D7Q26746947-3583907F-7B68-4FBA-A943-2469E72BDEF1Q26748461-B71391E1-D002-4498-8F8D-53EE0BA58E63Q26749020-94AEFFFE-D709-4284-BD0D-DB86A59EEB5BQ26749783-1188A813-4DFC-463C-89BB-410A7E8F973BQ26750955-5DC1D715-1326-4CBC-881F-014789F603A0Q26751147-2BE3BEDC-FBE6-4170-B785-2475ED916213Q26752583-700A4742-7729-4085-8E1E-E4E4B93764B3Q26752729-BC852112-1FD9-44CC-8E4B-66F36FC56287Q26752759-A9498985-AA15-4666-AF82-0CD86B864FACQ26767276-CF1E686A-0546-4281-8A61-AEF156851F01Q26774883-CD9FE4B6-EFF2-4FF7-A104-FE0C5DB12651Q26775340-7BAA54C5-B925-4836-8E8C-E6BA9EA6435EQ26777508-9F5733A5-77AB-4FBB-8597-740BEDC9F44AQ26778135-BE8885D8-2C22-4CA1-9B0A-1C5685651E06Q26798155-C90DF9C7-418C-4273-86C6-777C04350BDDQ26822513-1FCF735F-7040-410F-930B-2FC490618832Q27000114-E4CD7EA9-057A-4FBD-A53F-7850961D2DAEQ27006131-C20BA0E5-6B93-4A64-9926-D72F8B4D8CAEQ27021161-42A48E8F-0EC6-47BD-A8A0-FB52FA807601Q27301440-B68A8261-6755-410B-B427-6523E313C41AQ27318751-CF7F6083-1F0E-4C85-89CE-D54169E7E851Q27692035-30FD09B5-2A0D-4BB2-9BE5-D93A6041C89CQ28070303-FB54BFEA-AFA0-4B33-BAB4-AB14DA3281F4Q28070408-2DDBEF54-4CE1-456E-A614-B7BB6260FE55Q28076525-346108C6-6D8F-4BE7-8E9A-495BA94DB2B9Q28079077-2214BF31-09CE-4CB4-9E90-70C63C46C41CQ28079445-D820AE47-C1A1-4C2B-97CB-3A7DF3F2EA0CQ28079953-B0A939BA-C630-49DD-920F-B3A1CE5DA874Q28394768-888303E8-7AF3-408D-AD3B-42EB7903BCD5Q30244335-618F3F53-B963-4824-A54B-1CD6D9247693Q30248646-14D83458-F9B9-4A0D-AD2A-D3A69092B0EEQ30400120-FE5505A9-DBA6-4241-906A-2B8C770C35B2Q30401616-ADCB01EA-7C68-4B0A-A7B6-79DDE73EFB46Q30595695-8744CDF1-BED4-41FA-A535-927B25DBF26DQ33430862-50A409EE-A18A-4604-AF68-470867F9C06EQ33584964-15CD4375-339F-47C7-982E-D9BE65486E98Q33586821-184A1CD5-AC98-46F9-8960-81D25334BD1DQ33591227-EC79D626-ADAC-478B-85E3-71D92AEA262C
P2860
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
@en
type
label
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
@en
prefLabel
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
@en
P2093
P356
P1476
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
@en
P2093
Christopher P Day
Giovanni Targher
Quentin M Anstee
P2888
P304
P356
10.1038/NRGASTRO.2013.41
P407
P577
2013-03-19T00:00:00Z
P5875
P6179
1046343250